1. This wasn’t a strike on a single data center, it was strikes on many data centers.

2. Since that interview, AWS has started selling versions of their storage that isn’t redundant. It is not surprising that when AWS sells non-redundant storage that some data is not recoverable.

> This wasn’t a strike on a single data center, it was strikes on many data centers.

He didn't say "but if you hit many data centres then there is a problem". The premise was if you hit data centre, user won't notice, without caveat that there is a limit.

> Amazon's Matt Wood isn't worried: "If something does happen or we have a power event or there's a flood in one specific location, that data is held redundantly in other locations as well."

> Pogue asked, "I don't mean to give anyone ideas, but let's say I figured out that one of these unmarked buildings was an AWS data center, and I blew it up. Are you saying that it's so backed up and redundant that you probably wouldn't notice?"

Seems pretty silly to argue, but he certainly did say "one specific data center", and I don't think anyone even non-technical will conclude "it's safe if they all go down at once" from this statement.

The Iranians hit one specific data centre at a time, no?

Correct. Again, I don't think the implication you're making (that someone reading the original comment will think that is safe from a data recovery standpoint) is one any reasonable reader will make.

Is there anything more loathsome than an interviewee who fails to do the journalist's job for them?

That's an absurd interpretation.

She gave people medical test results that were incorrect. Say what you want about PE, the medical diagnostics firms they own provide accurate test results to patients.

We have an entire insurance industry that makes money denying care to Americans while they die, or are those okay deaths since it's done under the confines of shareholder value?

Those denials are literally the only thing in the entire system keeping costs down

Americans have the highest per capita healthcare spend for the lowest health metrics.

Because the only force keeping costs down is insurance death panels. One of our problems is that we don’t have enough death panels compared to our peers.

100%, author lives in Canada and the phrasing has the British heritage of Canadian English.

They do, they’re TPMs and PMs. If you’re a development team at Amazon stressing over MBRs, you’ve failed to give those people the tools to pull important metrics themselves.

Yeah, Amazon didn’t let its low margin retail business prevent them from taking high margins in AWS. I’m not sure why it is assumed Stripe would stay low margin.

This one is 158 Wh

I saw. Most entry-level ebikes have at least 10ah * 36v batteries; a few lightweight models have 7ah. So this has about half the battery capacity of the cheapest ebikes.

Given the size of it and the significantly less weight it adds to the bicycle, I'd say half capacity is pretty fantastic.

(Of course, "capacity" is misleading, as this will be less efficient than a real e-bike.)

> Which sort of affirms the mantra, "If you can't prove causation, try to prove correlation."

There’s already tons of correlation published for semaglutide lowering rates of dementia. This study is an effort at helping find the mechanism beyond the generally also known correlation that losing weight lowers rates of dementia.

> This is a Novo Nordisk-funded study focusing on predictive biomarkers rather than real-world dementia cases

You act like all this is hidden, but the title of the article and the list of authors makes this self-evident.

> Novo Nordisk's actual dedicated clinical trials for Alzheimer's completely failed to show that semaglutide stops cognitive decline

Sure, but the EVOKE studies were focused on something that could be sold as a product covered by insurance: semaglutide to those who had already developed Alzheimer’s. It is widely agreed the trial failed because it was a population already diagnosed with dementia. There’s lots of studies not funded by Novo that show semiglutatide has reduced the incidence of dementia in the diabetes population. Novo knows that running a general study on whether semaglutide reduces dementia in a non-diagnosed population is useless to their bottom line because insurance will never pay for everyone to take the drug.

It wasn't even funded in the way funding a study usually means. That an entity handed over money to a research group. The study was done by employers in their work time for their salary. Its a Novo Nordisk study, and as you say its right there in the open. Pointing an llm against the paper to (wrongly) realize this is a real tragedy of literacy.

I think it rubs plenty of laymen the wrong way to not make it a bit more explicitly known.

The world could use a bit less nuance in our headlines these days.

> [...] not make it a bit more explicitly known.

Honest question, how could it be made more explicitly known? It's literally under ACKNOWLEDGMENTS, in the most clear language possible.

The article title is fine. The title posted to HN (and other forums) should have outro or intro:

In a study funded by X, "Semaglutide linked to lower predicted dementia risk"

Or

"Semaglutide linked to lower predicted dementia risk", in a study funded by X.

This is a fair addendum that should be added when cross posting across websites. It need not be in the original link title. And this type of declaration should really follow most cross posted titles where a perceived bias/skepticism might otherwise be triggered without that knowledge being included. It's an explicit declaration upfront of potential conflicts.

It's never enough for purity tests.

You seem to be arguing that people shouldn't be skeptical, by default, of studies of products that are funded by the companies that make the products.

They funded this study as a prospective way of increasing the adoption and market share of their trademarked medication. It deserves skepticism.

There were woot offs 20 years ago. Flash sales are not some new scaling issue.

Its also not a solved one considering basically no platforms support them.

It's not? Shopify does it, woot does it, amazon does it, yes style does it, royal Caribbean does it.

Seems like a lot of places can do it for it not to be a solved problem.

I had an interesting internal debate the other day about whether farm fields were more natural than fields of solar panels. (Ignore fields that have both for now). To me, a tilled field that is being chemically fertilized and tilled is at this point just as far removed from the former native state.